• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

依前列醇对药物处置的影响。I:充血性心力衰竭患者中使用和未使用依前列醇时地高辛药代动力学的初步研究。

The effects of epoprostenol on drug disposition. I: A pilot study of the pharmacokinetics of digoxin with and without epoprostenol in patients with congestive heart failure.

作者信息

Carlton L D, Patterson J H, Mattson C N, Schmith V D

机构信息

School of Pharmacy, University of North Carolina at Chapel Hill, USA.

出版信息

J Clin Pharmacol. 1996 Mar;36(3):247-56. doi: 10.1002/j.1552-4604.1996.tb04195.x.

DOI:10.1002/j.1552-4604.1996.tb04195.x
PMID:8690819
Abstract

The influence of epoprostenol on the pharmacokinetics of drugs administered concurrently to patients with congestive heart failure (CHF) receiving epoprostenol was evaluated as a secondary objective of a Phase II pilot study. A total of 278 blood samples were collected from 30 patients with end-stage CHF receiving conventional therapy alone or conventional therapy plus epoprostenol. Estimates of oral clearance (Cl), volume of distribution, and absorption rate constant of digoxin were generated from plasma digoxin concentrations using nonlinear mixed effects modeling, and the effect of epoprostenol on Cl of digoxin was evaluated by univariate analysis. Additional factors that were evaluated by univariate analysis included age, obesity, time since study entry, cardiac output, concomitant use of angiotensin-converting enzyme (ACE) inhibitor, concomitant dobutamine, and estimated creatinine clearance. Backward elimination was used to arrive at a final model that included concomitant epoprostenol as a covariate. The final model revealed an approximate 15% decrease in Cl of digoxin in response to short-term administration of epoprostenol that was no longer apparent by the end of the 12-week treatment phase. Simulations revealed that this effect, although statistically significant, would not be clinically significant in most patients; however, the potential exists for short-term elevation of digoxin concentrations in response to concurrent administration of epoprostenol.

摘要

作为一项II期初步研究的次要目标,评估了依前列醇对接受依前列醇治疗的充血性心力衰竭(CHF)患者同时服用的药物药代动力学的影响。从30例仅接受常规治疗或接受常规治疗加依前列醇的终末期CHF患者中总共采集了278份血样。使用非线性混合效应模型从血浆地高辛浓度生成地高辛口服清除率(Cl)、分布容积和吸收速率常数的估计值,并通过单因素分析评估依前列醇对地高辛Cl的影响。通过单因素分析评估的其他因素包括年龄、肥胖、入组研究后的时间、心输出量、同时使用血管紧张素转换酶(ACE)抑制剂、同时使用多巴酚丁胺以及估计的肌酐清除率。采用向后剔除的方法得出最终模型,该模型将同时使用的依前列醇作为协变量。最终模型显示,短期给予依前列醇后,地高辛的Cl约降低15%,在12周治疗阶段结束时这种降低不再明显。模拟结果显示,尽管这种效应具有统计学意义,但在大多数患者中不会具有临床意义;然而,同时给予依前列醇可能会使地高辛浓度短期升高。

相似文献

1
The effects of epoprostenol on drug disposition. I: A pilot study of the pharmacokinetics of digoxin with and without epoprostenol in patients with congestive heart failure.依前列醇对药物处置的影响。I:充血性心力衰竭患者中使用和未使用依前列醇时地高辛药代动力学的初步研究。
J Clin Pharmacol. 1996 Mar;36(3):247-56. doi: 10.1002/j.1552-4604.1996.tb04195.x.
2
The effects of epoprostenol on drug disposition. II: A pilot study of the pharmacokinetics of furosemide with and without epoprostenol in patients with congestive heart failure.依前列醇对药物处置的影响。II:充血性心力衰竭患者中呋塞米在有和没有依前列醇情况下的药代动力学初步研究。
J Clin Pharmacol. 1996 Mar;36(3):257-64. doi: 10.1002/j.1552-4604.1996.tb04196.x.
3
Physiologic pharmacokinetic modeling of gastrointestinal blood flow as a rate-limiting step in the oral absorption of digoxin: implications for patients with congestive heart failure receiving epoprostenol.
J Pharm Sci. 1996 May;85(5):473-7. doi: 10.1021/js9503993.
4
Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model.地高辛在日本患者中的群体药代动力学:二室药代动力学模型
Clin Pharmacokinet. 2001;40(10):773-81. doi: 10.2165/00003088-200140100-00005.
5
[Effect of itraconazole on digoxin clearance in patients with congestive heart failure].
Yakugaku Zasshi. 2000 Sep;120(9):807-11. doi: 10.1248/yakushi1947.120.9_807.
6
Application of two-point assay of digoxin serum concentration in studying population pharmacokinetics in Egyptian pediatric patients with heart failure: does it make sense?
Am J Ther. 2005 Jul-Aug;12(4):320-7. doi: 10.1097/01.mjt.0000155108.62208.82.
7
Population pharmacokinetic analysis of digoxin in Chinese neonates and infants.地高辛在中国新生儿和婴儿中的群体药代动力学分析。
J Pharmacol Sci. 2014;125(2):142-9. doi: 10.1254/jphs.13233fp. Epub 2014 May 16.
8
Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling.应用非线性混合效应模型进行群体药代动力学分析以确定日本老年患者地高辛清除率从而优化药物治疗方案。
Drugs Aging. 2011 Oct 1;28(10):831-41. doi: 10.2165/11594230-000000000-00000.
9
Population pharmacokinetics of digoxin in elderly patients.老年患者地高辛的群体药代动力学
Eur J Drug Metab Pharmacokinet. 2013 Jun;38(2):115-21. doi: 10.1007/s13318-012-0107-8. Epub 2012 Oct 25.
10
Population pharmacokinetics of digoxin in Egyptian pediatric patients: impact of one data point utilization.埃及儿科患者地高辛的群体药代动力学:单个数据点利用的影响。
Am J Ther. 2002 Nov-Dec;9(6):492-8. doi: 10.1097/00045391-200211000-00006.

引用本文的文献

1
Pharmacokinetic Alterations in Patients with Chronic Heart Failure: A Systematic Review.慢性心力衰竭患者的药代动力学改变:一项系统评价。
Int J Mol Sci. 2025 Sep 28;26(19):9495. doi: 10.3390/ijms26199495.
2
Drug Interactions Associated With Therapies for Pulmonary Arterial Hypertension.与肺动脉高压治疗相关的药物相互作用
J Pharm Technol. 2022 Dec;38(6):349-359. doi: 10.1177/87551225221114001. Epub 2022 Aug 8.
3
Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).
心力衰竭患者药物的临床药代动力学:最新进展(第2部分,口服给药)
Clin Pharmacokinet. 2014 Dec;53(12):1083-114. doi: 10.1007/s40262-014-0189-3.